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Cisplatin resistanceIn a previous study, we reported that DNA damage induced apoptosis suppressor (DDIAS; hNoxin), a human ho-
molog of mouse Noxin, functions as an anti-apoptotic protein in response to DNA repair. Here we reveal that
DDIAS is a target gene of nuclear factor of activated T cells 2 (NFATc1) and is associated with cisplatin resistance
in lung cancer cells. In the DDIAS promoter analysis, we found that NFATc1 activated the transcription of DDIAS
through binding to NFAT consensus sequences in the DDIAS promoter. In addition, tissue array immunostaining
revealed a correlation between DDIAS and NFATc1 expression in human lung tumors. NFATc1 knockdown or
treatment with the NFAT inhibitor cyclosporine A induced apoptosis and led to growth inhibition of lung cancer
cells, indicating the functional relevance of both the proteins. In contrast, DDIAS overexpression overcame this
NFATc1 knockdown-induced growth inhibition, supporting the cancer-speciﬁc role of DDIAS as a target gene of
NFATc1. NFATc1 or DDIAS inhibition clearly enhanced apoptosis induced by cisplatin in NCI-H1703 and A549
cells. Conversely, DDIAS overexpression rescued NCI-H1703 cells from cisplatin-mediated cell death and
caspase-3/7 activation. These results suggest that NFATc1-induced DDIAS expression contributes to cisplatin re-
sistance, and targeting DDIAS or NFATc1 impairs the mechanism regulating cisplatin resistance in lung cancer
cells. Taken together, DDIAS is a target of NFATc1 and is associated with cisplatin resistance in lung cancer cells.
© 2015 Published by Elsevier B.V.1. Introduction
Nuclear factors of activated T cells (NFATs) regulate various cellular
functions involved in development and growth, immune responses, and
inﬂammatory responses [1–5]. Following an increase in the intracellular
calcium concentration, NFATc1-c4 are activated by the serine/threonine
phosphatase calcineurin and subsequently translocate to the nucleus to
transcribe target genes such as those encoding the cytokines IL-2, IL-4,
IFNγ, and TNFα and the chemokine CCL21 [1,4,6]. Stress-induced
NFAT5, a constitutive nuclear protein, is correlated with p38 MAPK-
mediated phosphorylation and expresses osmotic stress proteins andsis suppressor; hNoxin, human
mall interfering RNAs; NSCLC,
; GAPDH, glyceraldehyde 3-
orbol 12-myristate 13-acetate;
Center, KRIBB, 125 Kwahag-ro,cytokines [7]. Dysregulation of NFAT signaling is associated with malig-
nant phenotypes and tumor progression. NFATs, especially NFATc1
(NFAT1) and NFATc1 (NFAT2) are crucial for the regulation of cancer-
related functions such as cell survival and proliferation, invasive migra-
tion, and angiogenesis [1–3,8–12]. In particular, NFATc1 has been
suggested as an oncogene involved in various functions in cancer.
NFATc1 induces a tumorigenic microenvironment and activates signal
transducer and activator of transcription 3 (STAT3) in skin, pancreatic,
and ovarian cancer cells [3,11,13]. NFATc1 mutants that constitutively
localize to the nucleus have been reported to inhibit differentiation,
induce malignant transformation, and increase cell proliferation in
3T3-L1 ﬁbroblasts [14]. In addition, NFATc1 can also promote tumor
progression by the creation of a tumor cell population that possesses
stem cell characteristics with self-renewal capacities [15,16].
Cisplatin is a small-molecule platinum compound and is used for
treatment of various human cancers, including lung, ovarian, breast,
and bladder cancers. This agent induces DNA damage via intra-strand
cross-linkage and subsequently activates apoptosis in cancer cells [17].
Initially, cancer patients usually respond well to cisplatin chemothera-
py. However, the clinical effectiveness is signiﬁcantly reduced as the
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acquired or intrinsic cisplatin resistance.
Recently, we reported that DNA damage induced apoptosis suppres-
sor (DDIAS) or human Noxin (hNoxin) is highly expressed in lung
cancers [18,19]. Knockdown of DDIAS induced apoptosis in non-small
cell lung carcinoma A549 cells in response to DNA damage. On the
other hand, the research group led by Ze-Guang Han demonstrated
that overexpression of DDIAS via chromosomal ampliﬁcation promotes
cellular proliferation, colony formation, cellularmigration, and in vivo tu-
morigenicity in hepatocellular carcinoma (HCC) cells, whereas DDIAS
knockdownattenuated these effects [20]. As DDIAS is a recent topic of in-
terest in cancer societies, no reports of the transcriptional regulation and
therapeutic applications of DDIAS have been published. To evaluate
DDIAS as a potential therapeutic target in lung cancer, it is necessary to
elucidate its transcriptional regulation and clinical applications. We
therefore focused our study on the investigation of transcription factors
that regulate DDIAS expression, as well as the involvement and clinical
association of DDIAS in cancer treatment.
Here, we have demonstrated that the transcription factor NFATc1
regulates the expression of DDIAS by directly binding to its recognition
site in the DDIAS promoter. NFATc1 knockdown induced cellular
apoptosis, which was restored by DDIAS overexpression. Moreover,Fig. 1. Identiﬁcation of a functional DDIAS promoter. (A) Determination of the DDIAS transcripti
and translation starts at exon3. The DDIAS transcription start site was determined by 5′ rapid am
translation start site (ATG), primers R1 and R2, and promoter P1 are indicated. The DNA sequen
lation start codon ATG is in bold. (B) Analysis of theDDIAS promoter. DNA fragments P1–P5wer
Numbers represent the end points of each construct. Luciferase activitywas expressed in relative
P5 fragments (pGL-350/+125) containingwild-type (WT) ormutated (MN1–4)NFAT-binding
represent means ± standard errors of the means. **p b 0.01. (D) Reporter assay of the construinhibition of NFATc1 or DDIAS clearly enhanced apoptotic cell death in
lung cancer cells in the presence of cisplatin. Therefore, our ﬁndings
provide new insights into DDIAS-associated chemoresistance via
NFATc1 activation and contribute to strategies to overcome cisplatin
resistance in human lung cancer treatment.
2. Materials and methods
2.1. Determination of the transcription start site in the human DDIAS gene
using 5′ rapid ampliﬁcation of cDNA ends (RACE)
To identify the 5′UTRof humanDDIAS, 5′RACEwasperformed using
the SMART RACE cDNAAmpliﬁcation Kit (Clontech,Mountain View, CA,
USA) according to the manufacturer's protocol. First-strand cDNA was
synthesized using RNA from human embryonic kidney 293 (HEK293)
cells. 5′ RACE PCR was performed using the Advantage 2 PCR kit
(Clontech) and the following gene-speciﬁc primers: R1; 5′-TGTACCTG
TGCAAACCAGTGGCAGT-3′ or R2; 5′-AAAGCCTGCAATACCTGGGTCT
GGT-3′. The PCR products were separated by electrophoresis on 1.5%
agarose gels. After puriﬁcation using the QIAquick Gel Extraction Kit
(Qiagen, Valencia, CA, USA). PCR products were subcloned into the
pGEM-T vector using the TA Cloning Kit (Promega, Madison, WI, USA)on start site in human embryonic kidney (HEK) 293 cells.DDIAS gene consists of six exons,
pliﬁcation of cDNA ends (RACE) with R1 or R2 primers. The transcription start site (TSS),
ce isolated by 5′RACE is shown. The arrow indicates the transcription start site. The trans-
e ampliﬁed by PCR fromHEK293 cell genomic DNA and cloned into the pGL2-basic vector.
luciferase activity units (RLA) and normalized to pGL2-basic activity. (C) Reporter assay of
sites.MN1–4 contains pointmutations generated via site-directedmutagenesis. The values
ct P5–P8, from which NFAT-binding sites were deleted.
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transcription start site of the human DDIAS gene.
2.2. Reagents and plasmids
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO,
USA). The following antibodies were used: anti-NFATc2 (sc-7295×),
anti-NFATc1 (sc-7294×), anti-HDAC1 (sc-6298), anti-GFP (sc-8334),
anti-PARP1 (sc-7150), and anti-HA (sc-805) from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA); anti-RNA polymerase II (phosphor-Ser5,
#05-623B) from Millipore (Billerica, MA, USA); anti-HA (2367) and
anti-Caspase3 (9662) from Cell Signaling Technology (Beverly, MA,
USA); anti-GAPDH (LF-PA0212) from AbFrontier (Seoul, Korea); and
anti-Flag (F1804) and anti-DDIAS (HPA038540) from Sigma. The DNA
fragments of theDDIASpromoter (P1–P5), obtained fromHEK293 geno-
mic DNA, were ampliﬁed by PCR using the following primers: P1 for-
ward, 5′-ATGAGCTCGGGAAACCCAAAGCCA-3′; P2 forward, 5′-TCAGAG
CTCGCTAGCCCCTAGGACAGCGCC-3′; P3 forward, 5′-TCAGAGCTCGGA
GGCTCAGCGAAGCTC-3′; P4 forward, 5′-TCAGAGCTCGCTAAGCTCCACC
CTCTG-3′; P5 forward, 5′-TCAGAGCTCGCGGGAGATTCGATTGGAA-3′;
and reverse, 5′-TGCTCGAGCTTCCCGAGAACCCCTTTACC-3′. These DNA
fragments were subsequently inserted into the pGL2-basic luciferase
plasmid (Promega). MN1–MN4 mutants were generated using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA). N1; TTTCC to TTTAA, N2; GGAAA to TTAAA, N3; TTTCC to
TTTAA, N4; GGAAA to TTAAA. The following primers were used for mu-
tagenesis: MN1, 5′-CGGCTCACTCCACACTTTAACGGGAACCCTACG-3′;
MN2, 5′-GTTTGACGAAAATGGTCGTTTAAAGATGCTTGTAGGATTTCC-3′;Fig. 2.NFATc1 is involved inDDIAS transcription. (A) NFATc1 regulatesDDIAS promoter activity.
were subjected to a luciferase assay. The effect of NFAT knockdowneffect onDDIASmRNA levels
NFATc1 expressionwas analyzedbyRT-PCRandWestern blotting;NFATc1overexpression is sh
assay was performed using antibodies against control IgG, NFATc2, or NFATc1. PCR ampliﬁcat
shown in the top panel. For knockdown condition, HEK293 cells were transfected with siRNA
cells were pretreated with 10 μM cyclosporin A (CsA) for 1 h and subsequently treated with
DDIAS by cyclosporine A (CsA). HEK293 cells were transfected with the pGL2 or P5 constru
HEK293 cells were treated with NFATc1-speciﬁc siRNA and assayed for promoter activity. TheMN3, 5′-TTTCCAGATGCTTGTAGGATTTAATCGCTAAGCTCCACCCTC-3′;
and MN4, 5′-AAAGCGTTACTTCCGGCTTAAAAGGACGCGGGAGATTCGA-
3′. Flag-DDIAS vectors were cloned as previously described [19]. HA-
NFATc2 and HA-murine NFATc1 were kindly provided by Dr. Eun-
Sook Hwang at Ewha Woman's University and Nacksung Kim at
Chonnam National University, respectively. The DNA sequences of
NFATc2 and murine NFATc1 were conﬁrmed by sequence analysis.
2.3. Cell culture and transfection
HEK293 and non-small cell lung cancer A549 cells were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM); NCI-H1299 or NCI-
H1703 cells were cultured in RPMI-1640 containing 10% fetal bovine
serum (FBS), 50 U/mL of penicillin, and 50 μg/mL of streptomycin
(Invitrogen, Carlsbad, CA, USA). Cells were cultured in an incubator at
37 °C and 5% CO2. Cells were transfected with 40 nM siRNA via electro-
poration according to the manufacturer's instructions. The target se-
quences were as follows: NFATc2: 5′-GAAACUCCGACAUUGAACU-3′,
NFATc1: 5′-GGACUCCAAGGUCAUUUUC-3′, NFATc4: 5′-GCCCAGAAGU
UGGAAAGAGAU-3′, NFATc3: 5′-CGAGAUAAUUGGGAGAGACAU-3′,
DDIAS D1: 5′-GCCUAUCAUUUCCCUGAUC-3′, DDIAS D2: 5′-CUGUAACC
CAGGCAGAUGU-3′, or Scrambled: 5′-CCUACGCCACCAAUUUCGU-3′.
2.4. Luciferase reporter assays
Cells were co-transfected with the DDIAS promoter (P1–P5) and
pRL-TK, using 2 μL of Polyfect (Qiagen) per well. Cells were harvested
36 h after transfection and lysed in 1× passive lysis buffer. Fireﬂy andCells transfectedwith siRNAs for NFATc2, NFATc1, NFATc4, NFATc3, or control (scrambled)
is shown. (B) The effect of NFATc1 overexpression on promoter activity. NFATc2 ormurine
own to enhance the promoter activity. (C) Binding of NFATc1 to theDDIASpromoter. A ChIP
ions were performed using DDIAS promoter primers as indicated. The ChIP primer set is
against NFAT2 for 48 h. (D) Subcellular localization of NFATc1 in HEK293 cells. HEK293
100 nM PMA/1 μM A23187 (P/A) for 3 h. (E) Induction of DDIAS by P/A and inhibition of
ct and treated with P/A or CsA. (F) Effect of NFATc1 knockdown on promoter activity.
values are represented as means ± standard errors of the means. **p b 0.01.
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assay system (Promega) and a luminometer (Victor X Light; Perkin
Elmer, Waltham, MA, USA). Fireﬂy luciferase activity was normalized
to Renilla luciferase activity and expressed as the relative luciferase
activity (RLA) to reﬂect promoter activity.
2.5. RT-PCR
Total RNA was extracted from cells using TRIzol (Invitrogen) and
was reverse-transcribed into cDNA using TOPscript™ RT DryMIX
(dT18) (Enzynomics, Daejeon, Korea) according to the manufacturer's
instructions. The cycling conditions were 95 °C for 5 min, 95 °C for
30 s, 55 °C for 30 s, and 72 °C for 30 s. The following primers were
used: NFATc2 F, 5′-CATGGAAAACAAGCCTCTGG-3′; R, 5′-TTTTTGGGCT
CCAAGGGTAT-3′; NFATc1 F, 5′-GGGTTAAGTCCTCTCCCAAG-3′; R, 5′-
GGGTTAAGTCCTCTCCCAAG-3′; NFATc4 F, 5′-GAGGAACTGGTACTGACT
GG-3′; R, 5′-ATCACAGGCAGAAACCTGAA-3′; NFATc3 F, 5′-CTTGGATC
CCCTCTGACTTC-3′; R, 5′-AAGGGACCCAGCATAACAAA-3′; DDIAS F, 5′-
CTTGCAGCAGTTGTTACGAA-3′; R, 5′-GTGACCAAGCACTTCGAGTT-3′;
GAPDH F, 5′-TCATGACCACAGTCCATGCC-3′; and R, 5′-TCCACCACCCTG
TTGCTGTA-3′.
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as previously described [21,22] Chro-
matin was sheared by sonication on ice. The chromatin solution was
incubatedwith 2 μg of anti-NFATc2, anti- NFATc1, anti-RNA polymerase
II (phosphor-Ser5), or normal mouse immunoglobulin G (IgG; negative
control; Santa Cruz Biotechnology) overnight at 4 °C. These isolated
DNA fragments were subsequently used as templates for a PCR analysis.
Primerswere used to amplify the putative NFAT consensus binding sites
located in the DDIAS promoter region. The primerswere as follows: for-
ward for A, 5′-AAAAGGAGGCCAGCAGAAGCGC-3′; reverse for A, 5′-
GAGAGGAAAGTGGAGTGGAGG-3′; forward for B, 5′-GCACACGCATCA
TCTCCTCTA-3′; reverse for B, 5′-TGGGTGCAAGGAGCACAGTCT-3′;Fig. 3.DDIAS and NFATc1 expression correlate in human lung tumors. (A) Representative image
ing of a human tissue array, respectively. Scale bar, 50 μm. (B) The expression levels ofDDIAS or
in human lung tumors (p b 0.01; χ2 test). (D) Expression of NFATc1 andDDIAS in normal lung an
cancer cell lines NCI-H1703, A549, NCI-H1299, and NCI-H1437 are indicated. A Western blot aforward for C, 5′-TGCTAGCCCCTAGGACAGCGC-3′; reverse for C, 5′-
TCCCCGACAGGTGGATCAGTA-3′; forward for D, 5′-TACGCCCAGGAGGC
TCAGCGAA-3′; reverse for D, 5′-CCGCGTCCTTTTCCGCCGGAA-3′; for-
ward for GAPDH, 5′-TACTAGCGGTTTTACGGGCG-3′; reverse for
GAPDH, 5′-TCGAACAGGAGGAGCAGAGAGCGA-3′. All ChIP experiments
were performed at least twice.2.7. Immunoblotting assays
Cells were lysed with 1× RIPA buffer (Millipore) containing 1 mM
Na3VO4, 1 mM sodium ﬂuoride, 1 mM PMSF, and protease inhibitor
cocktail (Roche, Basel, Switzerland). For cell fractionation, nuclear
extracts were prepared as described previously [23]. The lysates were
quantiﬁed using a BCA assay kit (Bio-Rad, Hercules, CA, USA) and
subjected to immunoblotting with speciﬁc antibodies. Western blot
signals were detected using an enhanced chemiluminescence (ECL)
kit (Millipore).2.8. Cell viability, colony forming assay, and caspase 3/7 assays
Cell viability was determined using the sulforhodamine B assay, as
previously described [24]. The amount of sulforhodamine B dye bound
to the cell matrix was quantiﬁed using a spectrophotometer at
530 nm. To analyze apoptosis, the CellTox Green cytotoxicity assay
(Promega, Madison, WI, USA) and CellPlayer reagent-based caspase 3/
7 assays were performed. Images of cells were captured at 2-h intervals
using the IncuCyte ZOOM system (Essen Bioscience, Ann Arbor, MI,
USA), as previously described [22]. Green ﬂuorescence was divided by
cell conﬂuence and expressed as the relative ﬂuorescence. For colony
forming assay, cells transfected with NFATc1 or DDIAS siRNAs using
electrophoration were seeded 3000 cells/well onto a 6 well plate. Two
weeks later colonies were ﬁxed in 1% paraformaldehyde and stained
by 1% crystal violet solution.s ofDDIAS andNFATc1 detection via in situ hybridization and immunohistochemical stain-
NFATc1 are classiﬁed as 0, 1, 2, or 3. (C) Correlation betweenDDIAS and NFATc1 expression
d lung cancer cells. The normal cell linesWI-38, CCD34Lu, CCD39Lu, andHEK293 and lung
nalysis of NFATc1 and DDIAS in total cell lysates is shown.
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A parafﬁn-embedded human tissue array (Super BioChips, Seoul,
Korea)was analyzed viamRNA in situ hybridization using the ViewRNA
system (Affymetrix, Inc., Santa Clara, CA, USA) according to the
manufacturer's instructions.
2.10. Immunohistochemistry
Human tissue arrays (Super BioChips, Seoul, Korea) were
deparafﬁnized and hydrated. Antigen retrieval with citric acid
(pH 6.0) at 97 °C for 30 min was followed by treatment with 3% H2O2.
The slides were blocked with normal goat serum for 1 h and then hy-
bridized with antibodies against NFATc1 at 4 °C overnight. Next, the
slides were incubated with a biotinylated HRP complex (Vector Labora-
tories, Burlingame, CA, USA); 3,3-diaminobenzidine (DAB substrate kit;
Vector Laboratories) was used for color development. The slides were
counterstained with hematoxylin and eosin (H&E). An Olympus BX51
microscope equipped with a DP71 digital camera and DP-B software
(Olympus Co, Tokyo, Japan) was used to visualize the results. NFATc1
positive cells were deﬁned as 3+, 2+, 1+, or 0 by IHC. The human tis-
sue array was scored by two independent observers (JYI and KWL).
2.11. Statistical Analysis
The results are presented as means ± standard errors of the means.
Statistical analyses were performed using a two-tailed Student's t-test
or ANOVA followed by the Newman–Keuls test. The chi-square testFig. 4.NFATc1 knockdown induces apoptosis in lung cancer cells. (A) In a DDIAS promoter assa
before performing an NFATc1 knockdown and overexpression and luciferase assay. (B) Binding
control IgG and NFATc1 was performed. PCR ampliﬁcation was performed using the indicated
cyclosporin A on growth inhibition in the lung cancer cell lines NCI-H1703 and A549 or NCI-H
on the growth of the lung cancer cell lines NCI-H1703 andA549 orNCI-H1299. Cellswere transfe
B assay. (E) Induction of apoptosis by NFATc1 or DDIAS knockdown in lung cancer cells. PARP c
activity and cell cytotoxicity in NCI-H1703 cells treated with siNFATc1 or siDDIAS. Caspase3/7
aging system. Scale bar, 100 μm. Data are representative of triplicate experiments. The values a
forming assay. NCI-H1703 cells were transfected with siRNAs for NFATc1 or DDIAS and plated
image from two independent experiments with triplicate samples is shown.was used to analyze correlations. A p value of b0.05 was accepted to
be signiﬁcant.3. Results
3.1. Identiﬁcation of a DDIAS promoter
Wedetermined the transcription start site (TSS) ofDDIAS through 5′
RACE analysis using cDNA obtained from HEK293 cells (Fig. 1A). The
500-base pair (bp) and 700-bp fragments obtained with the R1 and
R2 primers were cloned and sequenced. An analysis of three indepen-
dent clones indicated that the transcription start site was located 212
nucleotides upstream of the DDIAS translation start site (ATG) at
exon3 (Fig. 1A, and Fig. 1 in Ref. [42]). RNA polymerase II (phospho-
Ser5) was clearly bound near the transcriptional start site region using
ChIP assay (Fig. 2 in Ref. [42]). Next, we determined theDDIAS promoter
region involved in transcriptional regulation to generate DDIAS mRNA.
We cloned a DNA fragment (P1,−2421 to+125) into the pGL2 vector,
which contains a ﬁreﬂy luciferase reporter gene (Fig. 1B). The P1 frag-
ment clearly promoted luciferase activity in HEK293 cells, suggesting
that this fragment contained the DDIAS promoter region. A sequence
analysis conducted with the TRANSFAC® program (Biobase Interna-
tional, Waltham, MA, USA) revealed that P1, which does not include a
TATA box, contains putative binding sites for the p300, C/EBP, SP1, and
NFAT transcription factors. In luciferase assays involving serial deletions
of P1, P5 (−350 to+125) was important for basal DDIAS transcription,
suggesting that this fragment contains a major regulatory site for DDIAS
transcription.y, NCI-H1703 or A549 cells were transfectedwith a DDIAS promoter reporter plasmid (P3)
of NFATc1 to theDDIAS promoter inNCI-H1703 cells. A ChIP assay using antibodies against
DDIAS promoter primers. The ChIP primer set is shown in the top panel. (C) The effect of
1299. Cells were treated with CsA (1 μM) for 48 h. (D) The effect of NFATc1 knockdown
ctedwith siNFATc1 or siDDIAS for 96 h. Cell growthwasmeasuredusing a sulforhodamine
leavage and caspase-3 activation were detected via Western blot analysis. (F) Caspase 3/7
activity and cell death were visualized as green ﬂuorescent signals using the IncuCyte im-
re represented as means ± standard errors of the means. *p b 0.05, **p b 0.01. (G) Colony
onto 6-well plates. Cells were observed twice weekly, ﬁxed and stained. A representative
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P5 had little effect on DDIAS promoter activity and DDIAS expression
at mRNA or protein levels (Fig. 3 in Ref. [42]). Apparently, P5 contains
four putative NFAT recognition sites (N1–N4) with the consensus
sequence GGAAA. Therefore, we generated point mutations (MN1–
MN4) at these NFAT recognition sites and observed signiﬁcant reduc-
tions in reporter activities with the MN1 and MN4 mutations, which
contained mutations in N1 and N4, respectively (Fig. 1C). Moreover,
deletions of N1 and N4 dramatically reduced promoter activities in the
assays involving serial deletion constructs of P5 (Fig. 1D). This result
suggests that the NFAT binding sites N1 and N4 are crucial for the
basal promoter activity necessary for DDIAS gene transcription.
3.2. DDIAS transcription is regulated by NFATc1
To determinewhichNFAT protein is involved inDDIAS transcription,
we investigated the effects of siRNA-mediated NFATc2, NFATc1,
NFATc4, or NFATc3 knockdown in HEK293 cells. Interestingly, only
NFATc1 knockdown suppressed both luciferase activity and basal
DDIAS mRNA expression, in contrast to NFATc2, NFATc4, or NFATc3
knockdown (Fig. 2A). Conversely, overexpression of NFATc1, but not
NFATc2, enhanced both P5 promoter activity and DDIAS mRNA levels
(Fig. 2B). Indeed, a ChIP assay revealed that endogenous NFATc1was re-
cruited to its NFAT binding sites, C and D, in the P5 region of the DDIAS
promoter in HEK293 (Fig. 2C). However, binding of NFATc1 to C and D
disappeared in NFATc1-depleted cells (Fig. 2C). These data suggest
that NFATc1 drives DDIAS transcription through direct binding to N1
and N4 in the DDIAS promoter.
3.3. NFATc1 activation induces DDIAS expression
Then, we examinedwhether calcium signaling could regulate DDIAS
transcription in HEK293 cells, as NFATc1 activity is regulated by theFig. 5.DDIAS overexpression prevents NFATc1-mediated growth inhibition. (A) Enforced expre
cells treatedwith NFATc1 siRNAwere transfectedwith Flag-DDIAS for 72 h. Cell growthwasme
PCR.Western blot analysis of PARP-1 and caspase-3 cleavage. (B, C)Measurements of caspase 3/
siNFATc1-treated cells was examined using CellPlayer caspase 3/7 reagent or CellTox Green rea
bar, 100 μm. Values are presented as fold changes in caspase3/7 activity relative to the scrambl
iments. The values are represented asmeans± SEM. *p b 0.05, **p b 0.01. (D, E) Overexpression
transfected with siDDIAS were transfected NFATc1 and then treated with cisplatin. Western blserine/threonine phosphatase calcineurin. NFATc1 is localized predom-
inantly in the nucleus; cyclosporin A (CsA), a calcineurin inhibitor, pre-
vents its nuclear translocation (Fig. 2D). CsA leads to nuclear export of
dephosphorylated NFATc1 upon intracellular Ca++ stimulation by
phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore
A23187. Combined treatment with PMA and A23187 (P/A) induced
DDIAS mRNA expression in HEK293 cells (Fig. 2E, and Fig. 4A in Ref.
[42]). Conversely, CsA signiﬁcantly suppressed P5 promoter activity
and DDIAS mRNA expression, which were restored by PMA/A23187
treatment (Fig. 2E, and Fig. 4B in Ref [42]). Likewise, NFATc1 knock-
down suppressed PMA/A23187-induced P5 promoter activity and re-
duced DDIAS mRNA levels (Fig. 2F). These results suggest that the
activation of NFATc1 signaling drives the transcriptional activation of
DDIAS.3.4. DDIAS expression correlates with NFATc1 expression in human lung
cancer
To evaluate the correlation between DDIAS and NFATc1 in lung can-
cer, we analyzed human lung tumor tissues using tissue array chips.We
performed in situ DDIASmRNA hybridization and NFATc1 protein im-
munohistochemistry staining in 108 human lung tumors and 9 normal
tissues (Fig. 3A). The expression levels of NFATc1 andDDIAS in these tis-
sues were evaluated according to the staining intensity (0–3) and clas-
siﬁed as low expression (0–1) or high expression (2–3) (Fig. 3B). High
DDIAS and NFATc1 expression levels were observed in 62.96% (68 of
108) and 61.11% (66 of 108) of tumor specimens, respectively, whereas
the expression of both proteinswas undetectable or weak in normal tis-
sues. Overall, 75% of tumors with positive NFATc1 staining (50 out of
66) displayed signiﬁcant increases in DDIAS expression, indicating a
clear correlation between DDIAS and NFATc1 (Fig. 3C). However, no
correlation was observed between the NFATc1/DDIAS expression levelsssion of Flag-DDIAS restored siNFATc1-induced cell growth inhibition. NCI-H1703 or A549
asured using a sulforhodamine B assay.DDIAS andNFATc1 expressionwasmeasured by RT-
7 activity (B) and cytotoxicity (C) inNCI-H1703 cells. The effect of DDIAS overexpression in
gent assays. Representative imageswere selected from the IncuCyte imaging system. Scale
ed siRNA-transfected control, which is set at 1. Data are representative of triplicate exper-
of NFATc1 failed to rescue cisplatin sensitivity in the absence of DDIAS inNCI-H1703. Cells
ot analysis (D) and cell viability assay by SRB (E) were performed.
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mainly contributes to a high level of DDIAS expression.
Next, we compared the expression levels of NFATc1 and DDIAS in
various cells. NFATc1 was strongly expressed in HEK293 cells but was
hardly detectable in lung ﬁbroblast WI-38, CCD34Lu, or CCD39Lu cells
(Fig. 3D). In contrast, NFATc1 expression was usually high and variable
in non-small cell lung cancer (NSCLC) cells, high in NCI-H1703 cells,
moderate in A549 and NCI-H1299 cells, and not observed in NCI-
H1437 cells. Similarly, DDIAS was strongly expressed in HEK293 cells
and cancer cells expressing high levels of NFATc1, but was hardly de-
tectable in ﬁbroblast cells and NCI-H1437 cells. This result indicates an
obvious correlation between the cellular expression levels of NFATc1
and DDIAS.
3.5. Inhibition of NFATc1 regulates survival in lung cancer cells
Previously, we demonstrated that DDIAS knockdown inhibited the
growth of lung cancer cells, but not normal cells. First, we assessed
whether DDIAS transcription was regulated by NFATc1 in the NCI-
H1703 and A549 lung cancer cells. NFATc1 knockdown clearly sup-
pressed luciferase activity, whereas overexpression enhanced luciferase
activity in both the cell lines (Fig. 4A). Furthermore, a ChIP assay re-
vealed the binding of NFATc1 to the P5 region of the DDIAS promoter
(Fig. 4B), thus supporting the NFATc1-mediated transcriptional regula-
tion of DDIAS in both lung cancer cells and HEK293 cells (Fig. 2). Next,
we tested whether NFATc1 suppression would also affect growth in
lung cancer cells. CsA clearly suppressed DDIASmRNA expression and
cell growth in NCI-H1703, A549, and NCI-H1299 cancer cells (Fig. 4C).
In addition, NFATc1 knockdown resulted in reducedDDIASmRNA levels
and growth inhibition in NCI-H1703, A549, and NCI-H1299 cells
(Fig. 4D). Western blot analysis of NFATc1- or DDIAS-knocked downFig. 6. Knockdown of NFATc1 or DDIAS in lung cancer cells sensitized to cisplatin. (A) The syner
H1703 or A549 cells were subjected to simultaneous cisplatin treatment and NFATc1 or DDIAS
or DDIAS knockdown. (C, D)Measurement of caspase 3/7 activity (C) and cytotoxicity (D) in NC
cisplatin treatment for 24 h. Values are presented as fold changes in caspase 3/7 activity relativ
triplicate experiments. The values are represented as means ± standard errors of the means. *cancer cells revealed PARP-1 cleavage and caspase-3 activation, indicat-
ing the subsequent apoptosis of lung cancer cells (Fig. 4E). However,
neither CsA treatment nor NFATc1 knockdown caused growth inhibi-
tion or apoptosis in HEK293 cells, even at reduced levels of DDIAS
mRNA expression, suggesting a cancer-speciﬁc, anti-apoptotic function
of DDIAS. To conﬁrm the induction of apoptosis resulting from NFATc1
knockdown, cytotoxicity and caspase assays were performed in NCI-
H1703 cells via CellTox and caspase 3/7 activity analyses, respectively
(Fig. 4F). Both caspase 3/7 activity and cell cytotoxicity increased dra-
matically when either NFATc1 or DDIAS was depleted. Next, NFATc1-
or DDIAS-deﬁcient NCI-H1703 cells were subjected to a colony-
forming assay (Fig. 4G). As expected, colony formationwas signiﬁcantly
suppressed in cells treated with si NFATc1 or siDDIAS. This result indi-
cates that both NFATc1 and DDIAS contribute to the suppression of ap-
optosis in lung cancer cells, but not in normal cells.
3.6. DDIAS overexpression relieved NFATc1 knockdown-mediated growth
inhibition
We have shown that DDIAS is a downstream target gene of NFATc1.
Therefore, we asked whether DDIAS overexpression could recover the
effects of NFATc1 knockdown in lung cancer cells. Overexpression of
Flag-DDIAS obviously relieved the growth inhibition induced by
NFATc1 knockdown in NCI-H1703 and A549 cells (Fig. 5A). RT-PCR
and Western blot analyses demonstrated both NFATc1 knockdown
and DDIAS overexpression. Apparently, DDIAS overexpression reversed
the apoptosis-related PARP-1 cleavage and caspase-3 activation in-
duced by NFATc1 knockdown in NCI-H1703 and A549 cells. Similarly,
caspase 3/7 activity, as measured via the CellPlayer assay, decreased
dramatically following DDIAS overexpression in NFATc1-depleted NCI-
H1703 cells (Fig. 5B). In a CellTox Green cytotoxicity assay, Flag-DDIASgistic effect of cisplatin on growth inhibition following NFATc1 or DDIAS knockdown. NCI-
knockdown. (B)Western blot analysis of cells subjected to cisplatin treatment and NFATc1
I-H1703 cells. Cells had been transfectedwith siRNA against NFATc1 or DDIAS, followed by
e to the scrambled siRNA-transfected control, which is set at 1. Data are representative of
p b 0.05, **p b 0.01.
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induced cell death (Fig. 5C). Subsequently, to prove that the NFATc1-
DDIAS axis controls cisplatin resistance, we also performed a rescue ex-
periment in which NFATc1 was overexpressed in DDIAS-depleted cells
(Fig. 5CD). Overexpression of HA-murine NFATc1 increased DDIAS ex-
pression and rescued cisplatin-induced growth inhibition in NCI-
H1703 cells. However, cisplatin-mediated growth inhibition was not
rescued in DDIAS-depleted cells. This result also supports DDIAS as a
target gene of NFATc1 and suggests that it plays a crucial role in the
NFATc1-mediated survival of cancer cells.
3.7. NFATc1/DDIAS is associated with cisplatin resistance in lung cancer
cells
Cisplatin is a highly effective chemotherapy drug used to treat lung
cancer. Previously, we showed that DDIAS overexpression restored
cisplatin-induced growth inhibition, thus suggesting the involvement
of DDIAS in defense mechanisms against DNA damage. Therefore, we
evaluated growth inhibition in NCI-H1703 and A549 cells following
simultaneous cisplatin treatment and NFATc1 or DDIAS depletion
(Fig. 6A). NFATc1 or DDIAS depletion with a low concentration of
siRNA enhanced the cisplatin-induced growth inhibition in both NCI-
H1703 and A549 cells. In addition, Western blotting revealed increased
PARP-1 cleavage and caspase 3 activation (Fig. 6B). CellPlayer reagent
and CellTox Green assays to determine caspase3/7 activity and cytotox-
icity, respectively, revealed that NFATc1 or DDIAS depletion clearly
enhanced cisplatin-induced cell death and caspase-3/7 activation in
NCI-H1703 cells (Fig. 6CD). Next, we investigated whether DDIAS
overexpression could restore cisplatin-mediated growth inhibition. As
expected, DDIAS overexpression rescued both NCI-H1703 and A549
cells from growth inhibition (Fig. 7A). Similarly, cisplatin-mediated
PARP-1 cleavage and caspase 3 activation were reversed by DDIASFig. 7.DDIAS overexpression recovers growth inhibition in cisplatin-treated cells. (A) The effect
of DDIAS-overexpressing cells treatedwith cisplatin. (C, D)Measurement of caspase 3/7 activity
in-treated cellswas examined through CellPlayer caspase 3/7 reagent or CellTox Green reagent a
siRNA-transfected control, which is set at 1. Data are representative of triplicate experiments. T
Representative images were selected from the IncuCyte imaging system. Scale bar, 100 μm.overexpression in both NCI-H1703 and A549 cells (Fig. 7B). Moreover,
DDIAS overexpression clearly rescued NCI-H1703 cells from cisplatin-
mediated cell death and caspase-3/7 activation (Fig. 7CD). This ﬁnding
conﬁrms that NFATc1-mediated DDIAS expression contributes to
cisplatin resistance in lung cancer cells.
4. Discussion
Previously, we reported that hNoxin, the human homolog of mouse
Noxin, is highly expressed in lung cancer. Knockdown of hNoxin in-
duced apoptosis in lung cancer A549 cells. In contrast, overexpression
of hNoxin suppressed apoptosis in response to DNA-damaging agents,
suggesting that hNoxin has an anti-apoptotic function that protects
against DNA lesions. Accordingly, hNoxinwas renamedDNAdamage in-
duced apoptosis suppressor (DDIAS) and was suggested as a potential
therapeutic target in lung cancer. Therefore, an understanding of how
DDIAS is regulated at the transcriptional level and its association with
the therapeutic properties in lung cancer is needed. Herein, we have
described the transcriptional regulation of DDIAS by NFATc1 and the
relevance of this mechanism to cisplatin resistance in lung cancer cells.
To study the DDIAS transcriptional mechanism, we ﬁrst determined
the transcription start site to be located 212 nucleotides upstreamof the
translation start site (ATG) of the DDIAS gene. Next, we performed pro-
moter analysis using the reporter assay involving serial DNA fragments
upstream of the DDIAS transcription start site. We found that the P5 re-
gion (−350 to +125), which contains GGAAA consensus sequences,
was crucial for the transcriptional activation of DDIAS. In fact, 11.5 kb-
and 1.3 kb-long introns exist upstream of exons 2 and 3 respectively, in-
dicating that the ATG translation start site in exon 3 is far from the P5
promoter. Non-coding introns often perform several regulatory tasks
such as transcription, polyadenylation, mRNA export, translational efﬁ-
ciency, andmRNA decay rate monitoring [25]. Moreover, a TRANSFAC®of DDIAS overexpression on the growth of cisplatin-treated cells. (B)Western blot analysis
(C) and cytotoxicity (D) in NCI-H1703 cells. The effect of DDIAS overexpression in cisplat-
ssays. Values are presented as fold changes in caspase 3/7 activity relative to the scrambled
he values are represented as means ± standard errors of the means. *p b 0.05, **p b 0.01.
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factor binding sites in the intron between exons 1 and 2. Although this
study has not demonstrated clear evidence of introns in the transcrip-
tional regulation of DDIAS, these elements may play a role in various
regulatory mechanisms such as enhancement, repression, and alterna-
tive DDIAS splicing.
Because NFAT proteins bind to this GGAAA consensus sequence, we
next examined which NFAT would bind to the DDIAS promoter by ex-
amining the effects of NFAT isoform knockdown and overexpression
on the luciferase activity and ChIP assays. The results clearly demon-
strated that NFATc1 alone drove DDAS transcription through direct
binding to GGAAA at both the N1 and N4 sites in the DDIAS promoter.
Therefore, we suggest that DDIAS is a downstream target gene of
NFATc1. NFATc1 is known to undergo calcineurin-mediated activation
following an increase in intracellular calcium, and once activated,
NFATc1 translocates to the nucleus to induce transcription of its target
genes.We conﬁrmed that PMA and the calcium ionophore A23187 acti-
vated P5 promoter activity and DDIAS mRNA expression, whereas the
calcineurin inhibitor CsA signiﬁcantly suppressed these processes by
promoting the nuclear export of NFAT. However, PMA/A23187 did not
fully restore P5 promoter activity and reduced DDIAS mRNA levels in
CsA-treated cells. Most likely, Ca signal inhibition was maintained in
the presence of CsA, whereas PMA induced another transcription factor
with a role in DDIAS activation. Therefore, although NFATc1 appears to
be essential, other factors may contribute to DDIAS activation. More-
over, we demonstrated a role of CsA as a NFAT inhibitor in the suppres-
sion of DDIAS transcription. However, CsA also affects T cell receptor
(TCR)-induced NFκB activity [26–28] and Elk-1 phosphatase activity
[29].
Next, we investigated the correlation between NFATc1 and
DDIAS expression in lung tumors. Through a tissue array analysis,
we observed a strong correlation between NFATc1 and DDIAS in
tumor tissues. Furthermore, the NFATc1 and DDIAS expression
levels were similar in lung cancer cells. We also assessed the func-
tional correlation between NFATc1 and DDIAS. NFATc1 inhibition
through knockdown or CsA treatment led to reduced DDIAS expres-
sion and apoptosis in lung cancer cells. Conversely, DDIAS overex-
pression relieved cells from the effects of NFATc1 knockdown,
thus supporting the cancer-speciﬁc role of DDIAS as a target gene
of NFATc1.
NFATc1 and NFATc2, the prevalent NFAT members in peripheral T
cells, control not only effector functions but also cell cycle and apoptosis
in T cells [2,30,31]. Although NFATc1 and NFATc2 share 72% sequence
similarity in their DNA binding domains, they exert different functions
in cells [1,2,8]. NFATc1 deletion is generally more deleterious than
NFATc2 deletion. NFATc1-deﬁcient mouse embryos die because of de-
velopmental defects in cardiac valves and septa, whereas NFATc2-
deﬁcient mice do not. Both NFATc1 and NFATc2 are activated or
overexpressed in human solid tumors and hematological malignancies.
NFATc1 appears to act as an oncoprotein by inducing transformation in
NIH 3T3 cells and cell growth in solid tumors, despite frequent reports
of the involvement of NFATc2 in migration and invasion. In contrast,
NFATc2 functions as a tumor suppressor to induce apoptosis and cell
cycle arrest and has been shown to inhibit HRASV12-induced transfor-
mation [3,8].
NFATc1 exists as three distinct isoforms: NFATc1A, NFATc1B, and
NFATc1C [32,33]. Themost abundant short isoform, NFATc1A, is formed
by transcription at the strong NFATc1 promoter P1 and polyadenylation
at proximal pA1 [32,34]. In addition, a high level of NFATc1A expression
is induced by the positive autoregulation of NFAT transcription factors.
In contrast, the longer NFATc1B and NFAT2C isoforms are formed by
weak transcription at the P2 promoter and polyadenylation at distal
pA2 and are not affected by autoregulation. NFATc1A does not promote
apoptosis and thereby enhances the effector functions of effector T cells
[32]. Moreover, NFATc1A overexpression in NIH3T3 cells leads to an in-
creased proliferation capacity and induction of cell transformation [8].Accordingly, NFATc1 mutation or dysregulation contributes to tumori-
genesis and tumor progression by linking inﬂammatory and calcium
signaling to cell proliferation and survival.
Recently, accumulating evidence indicates thatNFATc1plays a crucial
role in cancer-related functions, especially in pancreatic cancer. NFATc1
is strongly expressed in the pancreatic cancer cell line Panc-1. In these
cells, NFATc1 induces cell transformation and anchorage-independent
cell growth and acts co-operatively with Stat3 to mediate malignant
transformation [3,13]. In addition, NFATc1 mediates the activation of c-
Myc transcription [3,35]. We found that NFATc1 knockdown reduced
DDIAS mRNA levels and growth inhibition in Panc-1 cells (Fig. 5 in Ref
[42]). Therefore, we speculate that NFATc1/DDIAS signaling might also
occur in solid tumors other than lung and pancreatic cancers.
Drug resistance is a major complication of cancer chemotherapy
and accounts for the failure of chemotherapy to cure the majority
of cancer patients [36,37]. To assess whether DDIAS is associated
with chemoresistance in lung cancer cells, we compared growth in-
hibition in cells expressing different amounts of NFATc1 and DDIAS
in the presence of cisplatin, which is widely used for lung cancer
therapy. Interestingly, NFATc1 or DDIAS knockdown signiﬁcantly en-
hanced cisplatin-mediated apoptosis by sensitizing NCI-H1703 and
A549 lung cancer cells to cisplatin. Accordingly, we have provided
clear evidences to support the contribution of NFATc1-mediated
DDIAS expression to cisplatin resistance in lung cancer cells.
Cisplatin exerts its anti-cancer effects via multiple mechanisms;
however, its most crucial mode of action involves the generation of
DNA lesions, followed by activation of the DNA damage response and
apoptosis [38,39]. Currently, we are investigating the involvement of
DDIAS in cisplatin-induced DNA damage repair in lung cancer cells. In
addition, combination therapies of cisplatin and other cancer drugs
have been applied to improve drug efﬁcacies during cancer treatment.
In lung cancers, a combination of vindesine and cisplatin appears to be
effective [40]. Moreover, olaparib and cisplatin have a synergistic effect
on PTEN-deﬁcient lung cancer cells [41]. We expect that a chemical
compound or DDIAS targeting could be effectively used in combination
with cisplatin for the treatment of lung cancer.
To date, most studies on the function of NFATc1 in cancer have in-
volved lymphoma, leukemia, skin cancer, ovarian cancer, or pancreatic
cancers. Here, we report the relatively strong expression of NFATc1 in
most investigated lung tumor tissues. Furthermore, we have shown
that the genetic and pharmacological regulation of NFATc1 affects
DDIAS expression in lung cancer cells. As shown previously, DDIAS
knockdown in the normal cell lines HEK293, WI-38, and CCD-34Lu did
not suppress cell growth [19]. Likewise, NFATc1 knockdown in
HEK293 cells did not affect cell growth, in contrast to NFATc1 knock-
down in NCI-H1703 or A549 lung cancer cells, which caused severe
growth inhibition. This observation suggests that NFATc1/DDIAS may
play a crucial role in the speciﬁc defense or survival of cancer cells, but
not normal cells.
In conclusion,DDIAS transcription is activated by recruiting NFATc1 to
NFAT binding sites in the DDIAS promoter. A positive correlation was ob-
served between the expression of NFATc1 and DDIAS in human lung
tumor tissues and cancer cells. Moreover, NFATc1 and DDIAS both con-
tribute to cisplatin resistance as well as survival in lung cancer cells. This
evidence provides mechanistic insights into the anti-apoptotic function
of DDIAS and links NFATc1 immune-related signaling to chemoresistance
in lung cancer cells.
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